| 达非那新 |
| |
| 引用本文： | 梁晓丽,胡咏川,张玉风,吴娜,左明新.达非那新[J].中国新药杂志,2006,15(20):1790-1791. |
| |
| 作者姓名： | 梁晓丽 胡咏川 张玉风 吴娜 左明新 |
| |
| 作者单位： | 卫生部北京医院药学部,北京,100730 |
| |
| 摘 要： | 达非那新是一种选择性M3受体阻滞剂，临床主要用于治疗膀胱过度活动综合征。它能明显减少尿失禁和排尿次数，降低尿急的程度，有良好的耐受性。常见的不良反应为口干和便秘，对中枢神经系统和认知功能的影响与安慰剂相似。
|
| 关 键 词： | 达非那新 膀胱过度活动综合征 M3受体阻滞剂 |
| 文章编号： | 1003-3734（2006）20-1790-02 |
| 收稿时间： | 2006-01-24 |
| 修稿时间： | 2006年1月24日 |
Pharmacology and clinical application of darifenacin |
| |
| LIANG Xiao-li,HU Yong-chuan,ZHANG Yu-feng,WU Na,ZUO Ming-xin.Pharmacology and clinical application of darifenacin[J].Chinese Journal of New Drugs,2006,15(20):1790-1791. |
| |
| Authors: | LIANG Xiao-li HU Yong-chuan ZHANG Yu-feng WU Na ZUO Ming-xin |
| |
| Institution: | Department of Pharmacy, Beijing Hospital, Ministry of Health, Beijing 100730, China |
| |
| Abstract: | Darifenacin is a selective muscarinic M3-receptor antagonist that has been used in patients with overactive bladder syndrome (OAB). Darifenacin can reduce the frequency of urinary incontinence and frequency and severity of urgency in patients with OAB. The most common adverse events are dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. Darifenacin had no changes on cognitive function in healthy elderly volunteers. |
| |
| Keywords: | darifenacin overactive bladder syndrome (OAB) M3-receptor antagonist |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
